Abstract
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice. The prevalence of AF increases with age. Indeed, there is one in four chance for both men and women aged 40 and above to develop AF during their life.1 With the increase in aging population, AF has become a major condition that requires extra resources in its management as well as the complications associated with it.
Keywords
- Beta Blocker
- Paroxysmal Atrial Fibrillation
- Atrial Fibrillation Patient
- Antithrombotic Therapy
- Persistent Atrial Fibrillation
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation. 2004;110:1042-1046.
Fox CS, Parise H, D’Agostino RB Sr, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA. 2004;291:2851-2855.
Waldo AL. Mechanism of atrial fibrillation. J Cardiovasc Electrophysiol. 2003;14(12 Suppl): S267-S274.
Saffitz JE. Connexins, conduction, and atrial fibrillation. N Engl J Med. 2006;354(25):2712-2714.
Watson T, Shantsila E, Lip GYH. Mechanisms of thrombogenesis in atrial fibrillation. Virchow’s triad revisited. Lancet 2008;372.
National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: national clinical guideline for management in primary and secondary care. London: Royal College of Physicians, 2006 (http://rcplondon.ac.uk/pubs/books/af/index.asp).
Lip GY, Tse HF. Management of atrial fibrillation. Lancet. 2007;370:604-618.
Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, Crijns HJ, RACE and AFFIRM. Does intensity of rate-control influence outcome in artial fribrillation. An analysis of pooled date from the RACE and AFFIRM studies. Europace. 2006; 8:935–942.
Li Saw Hee FL, Lip GYH. Digoxin revisited. QJM. 1998; 91:259-264.
Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol. 2003;91:15-26D.
Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD Jr, Raisch DW, Ezekowitz MD, Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861-1872.
Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):546S-592S.
Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med. 2004;351:2384-2391.
Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation – pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet. 2000; 356:1789-1794.
Testa L, Biondi-Zoccai GG, Dello Russo A, Bellocci F, Andreotti F, Crea F. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J. 2005;26(19):2000-2006.
Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667-2677.
Rawles JM. What is meant by a ‘controlled’ ventricular rate in atrial fibrillation? Br Heart J. 1990;63:157-161.
Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carverdilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003;42:1944-1951.
Segal JB, McNamara RL, Miller MR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract. 2000;49:47-59.
Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open label study of five drug regimens. J Am Coll Cardiol. 1999; 33:304-310.
Roth A, Harrison E, Mitani G, Cohen J, Rahimtoola SH, Elkayam U. Efficacy and safety of medium-and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation. 1986;73:316-324.
Saksena S, Madan N. Hybrid therapy of atrial fibrillation: algorithms and outcome. J Interv Card Electriohysiol. 2003;9:235-247.
Oral H, Knight BP, Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation. 2002;105:1077-1081.
Marrouche NF, Martin DO, Wazni O, et al. Phased-array intracardiac echocardiography monitoring during pulmonary vein isolation in patients with atrial fibrillation: impact on outome and complications. Circulation. 2003; 107: 2710-2716.
Oral H, Chugh A, Good E, et al. A tailored approach to catheter ablation of paroxysmal atrial fibrillation. Circulation. 2006;113:1824-1831.
Healey JS, Toff WD, Lamas GA, et al. Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data. Circulation. 2006;114:11-17.
Friedman PA, Dijkman B, Warman EN, et al. Atrial therapies reduce atrial arrhythmia burden in defibrillator patients. Circulation. 2001;104:1023-1028.
Lip GY, Boss CJ. Antithrombotic treatment in atrial fibrillation. Heart. 2006;92:155-161.
Hughes M, Lip GY, Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008;99(2):295-304.
Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110: 2287-2292.
Hughes M, Lip GY, on behalf of the Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007;100:599-607.
Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-1839.
Boos CJ, Lip GY. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. J Hum Hypertens. 2005;19:855-859.
Boos CJ, Anderson R, Lip GYH. Is atrial fibrillation an inflammatory disorder? Eur Heart J. 2006;27:136-149.
Stiles S. Dronedarone safety, efficacy standings bolstered in huge atrial-fibrillation trial. theheart.org. [HeartWire > Electrophysiology]; May 19, 2008. Available at: http://www.theheart.org/article/867591.do. Accessed June 24, 2008.
Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest, 2010; 137, 263-272.
Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010;Mar 18.[Epub]. doi: 10.1378/chest.10-134.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag London Limited
About this chapter
Cite this chapter
Khoo, C.W., Lip, G.Y.H. (2010). Atrial Fibrillation: Non Surgical Management. In: Bonser, R., Pagano, D., Haverich, A. (eds) Mitral Valve Surgery. Springer, London. https://doi.org/10.1007/978-1-84996-426-5_13
Download citation
DOI: https://doi.org/10.1007/978-1-84996-426-5_13
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84996-425-8
Online ISBN: 978-1-84996-426-5
eBook Packages: MedicineMedicine (R0)